Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05956821 · ClinicalTrials.gov registry record · Phase 1
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
A Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05956821 is a Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 20 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05956821, a Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
Conditions Studied
Interventions
- DRUG SIACI of cetuximab and bevacizumab
Study Locations (1)
Florida
- Jackson Memorial Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05956821
The ClinicalTrials.gov registry entry for NCT05956821 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (79% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which SIACI of cetuximab and bevacizumab is the first listed.
NCT05956821 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05956821 about?
NCT05956821 is a clinical study titled "Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age". This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
What is the current status of trial NCT05956821?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-19. Estimated completion is 2029-12-01.
What conditions does trial NCT05956821 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Diffuse Intrinsic Pontine Glioma, Oligodendroglioma, H3 K27M.
What interventions are being tested in trial NCT05956821?
The interventions under investigation include: SIACI of cetuximab and bevacizumab (DRUG).
Who is sponsoring clinical trial NCT05956821?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05956821 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
-
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.